MUNTEL Film-coated tablet Ref.[49855] Active ingredients: Levocetirizine

Source: Health Products Regulatory Authority (IE)  Revision Year: 2019  Publisher: UCB (Pharma) Ireland Limited, United Drug House, Magna Drive, Magna Business Park, Citywest Road, Dublin 24, Ireland

4.3. Contraindications

Hypersensitivity to the active substance, to cetirizine, to hydroxyzine or to any piperazine derivatives or to any of the other excipients listed in section 6.1.

Severe renal impairment at less than 10 ml/min creatinine clearance.

4.4. Special warnings and precautions for use

Precaution is recommended with concurrent intake of alcohol (see section 4.5).

Caution should be taken in patients with predisposing factors of urinary retention (e.g. spinal cord lesion, prostatic hyperplasia) as levocetirizine may increase the risk of urinary retention.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Paediatric population

The use of the film-coated tablet formulation is not recommended in children aged less than 6 years since this formulation does not allow for appropriate dose adaptation. It is recommended to use a paediatric formulation of levocetirizine.

4.5. Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed with levocetirizine (including no studies with CYP3A4 inducers); studies with the racemate compound cetirizine demonstrated that there were no clinically relevant adverse interactions (with antipyrine, azithromycin, cimetidine, diazepam, erythromycin, glipizide, ketoconazole and pseudoephedrine). A small decrease in the clearance of cetirizine (16%) was observed in a multiple dose study with theophylline (400 mg once a day); while the disposition of theophylline was not altered by concomitant cetirizine administration.

In a multiple dose study of ritonavir (600 mg twice daily) and cetirizine (10 mg daily), the extent of exposure to cetirizine was increased by about 40% while the disposition of ritonavir was slightly altered (-11%) further to concomitant cetirizine administration.

The extent of absorption of levocetirizine is not reduced with food, although the rate of absorption is decreased.

In sensitive patients, the concurrent administration of cetirizine or levocetirizine and alcohol or other CNS depressants may cause additional reductions in alertness and impairment of performance.

4.6. Fertility, pregnancy and lactation

Pregnancy

There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of levocetirizine in pregnant women. However, for cetirizine, the racemate of levocetirizine, a large amount of data (more than 1000 pregnancy outcomes) on pregnant women indicate no malformative or feto/neonatal toxicity. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryo/fetal development, parturition or postnatal development (see section 5.3). The use of levocetirizine may be considered during pregnancy, if necessary.

Breast-feeding

Cetirizine, the racemate of levocetirizine, has been shown to be excreted in human. Therefore, the excretion of levocetirizine in human milk is likely. Adverse reactions associated with levocetirizine may be observed in breastfed infants. Therefore, caution should be exercised when prescribing levocetirizine to lactating women.

Fertility

For levocetirizine no clinical data are available.

4.7. Effects on ability to drive and use machines

Comparative clinical trials have revealed no evidence that levocetirizine at the recommended dose impairs mental alertness, reactivity or the ability to drive. Nevertheless, some patients could experience somnolence, fatigue and asthenia under therapy with Levocetiririzine. Therefore, patients intending to drive, engage in potentially hazardous activities or operate machinery should take their response to the medicinal product into account.

4.8. Undesirable effects

Clinical studies

Adults and adolescents above 12 years of age

In therapeutic studies in women and men aged 12 to 71 years, 15.1% of the patients in the levocetirizine 5 mg group had at least one adverse drug reaction compared to 11.3% in the placebo group. 91.6 % of these adverse drug reactions were mild to moderate.

In therapeutic trials, the dropout rate due to adverse events was 1.0% (9/935) with levocetirizine 5 mg and 1.8% (14/771) with placebo.

Clinical therapeutic trials with levocetirizine included 935 subjects exposed to the medicinal product at the recommended dose of 5 mg daily. From this pooling, following incidence of adverse drug reactions were reported at rates of 1% or greater (common: ≥1/100 to <1/10) under levocetirizine 5 mg or placebo:

Preferred Term
(WHOART)
Placebo (n=771) Levocetirizine 5 mg
(n= 935)
Headache 25 (3.2%) 24 (2.6%)
Somnolence 11 (1.4%) 49 (5.2%)
Mouth dry 12 (1.6%) 24 (2.6%)
Fatigue 9 (1.2%) 23 (2.5%)

Further uncommon incidences of adverse reactions (uncommon ≥1/1,000 to <1/100) like asthenia or abdominal pain were observed.

The incidence of sedating adverse drug reactions such as somnolence, fatigue, and asthenia was altogether more common (8.1%) under levocetirizine 5 mg than under placebo (3.1%).

Paediatric population

In two placebo-controlled studies in paediatric patients aged 6-11 months and aged 1 year to less than 6 years, 159 subjects were exposed to levocetirizine at the dose of 1.25 mg daily for 2 weeks and 1.25 mg twice daily respectively. The following incidence of adverse drug reactions was reported at rates of 1% or greater under levocetirizine or placebo.

System Organ Class and Preferred Term Placebo (n=83) Levocetirizine (n=159)
Gastrointestinal disorders
Diarrhoea 0 3 (1.9%)
Vomiting 1 (1.2%) 1 (0.6%)
Constipation 0 2 (1.3%)
Nervous system disorders
Somnolence 2 (2.4%) 3 (1.9%)
Psychiatric disorders
Sleep disorder 0 2 (1.3%)

In children aged 6-12 years double blind placebo controlled studies were performed where 243 children were exposed to 5 mg levocetirizine daily for variable periods ranging from less than 1 week to 13 weeks. The following incidence of adverse drug reactions was reported at rates of 1% or greater under levocetirizine or placebo.

Preferred TermPlacebo (n=240) Levocetirizine 5mg (n=243)
Headache 5 (2.1%) 2 (0.8%)
Somnolence 1 (0.4%) 7 (2.9%)

Post-marketing experience

Adverse reactions from post-marketing experience are per System Organ Class and per frequency. The frequency is defined as follows: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).

Immune system disorders

Not known: hypersensitivity including anaphylaxis

Metabolism and nutrition disorders

Not known: increased appetite

Psychiatric disorders

Not known: aggression, agitation, hallucination, depression, insomnia, suicidal ideation

Nervous system disorders

Not known: convulsion, paraesthesia, dizziness, syncope, tremor, dysgeusia

Ear and labyrinth disorders

Not known: vertigo

Eyes disorders

Not known: visual disturbances, blurred vision, oculogyration

Cardiac disorders

Not known: palpitations, tachycardia

Respiratory, thoracic, and mediastinal disorders

Not known: dyspnoea

Gastrointestinal disorders

Not known: nausea, vomiting, diarrhoea

Hepatobiliary disorders

Not known: hepatitis

Renal and urinary disorders

Not known: dysuria, urinary retention

Skin and subcutaneous tissue disorders

Not known: angioneurotic oedema, fixed drug eruption, pruritus, rash, urticaria

Musculoskeletal, connective tissues, and bone disorders

Not known: myalgia, arthralgia

General disorders and administration site conditions

Not known: oedema

Investigations

Not known: weight increased, abnormal liver function tests

Description of selected adverse reactions

After levocetirizine discontinuation, pruritus has been reported in a very small number of patients.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.

6.2. Incompatibilities

Not applicable.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.